These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

582 related items for PubMed ID: 16108837

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Review article: the metabolic syndrome and non-alcoholic fatty liver disease.
    Loria P, Lonardo A, Carulli L, Verrone AM, Ricchi M, Lombardini S, Rudilosso A, Ballestri S, Carulli N.
    Aliment Pharmacol Ther; 2005 Nov; 22 Suppl 2():31-6. PubMed ID: 16225469
    [Abstract] [Full Text] [Related]

  • 23. Weight loss: cornerstone in the treatment of non-alcoholic fatty liver disease.
    Tilg H, Moschen A.
    Minerva Gastroenterol Dietol; 2010 Jun; 56(2):159-67. PubMed ID: 20485253
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. From the metabolic syndrome to NAFLD or vice versa?
    Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Järvinen H, Svegliati-Baroni G.
    Dig Liver Dis; 2010 May; 42(5):320-30. PubMed ID: 20207596
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. A fresh look at NASH pathogenesis. Part 1: the metabolic movers.
    Larter CZ, Chitturi S, Heydet D, Farrell GC.
    J Gastroenterol Hepatol; 2010 Apr; 25(4):672-90. PubMed ID: 20492324
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Review article: steatosis, the metabolic syndrome and cancer.
    Bugianesi E.
    Aliment Pharmacol Ther; 2005 Nov; 22 Suppl 2():40-3. PubMed ID: 16225471
    [Abstract] [Full Text] [Related]

  • 30. Nonalcoholic fatty liver disease: defining a common problem.
    Gasbarrini G, Vero V, Miele L, Forgione A, Hernandez AP, Greco AV, Gasbarrini A, Grieco A.
    Eur Rev Med Pharmacol Sci; 2005 Nov; 9(5):253-9. PubMed ID: 16231586
    [Abstract] [Full Text] [Related]

  • 31. Hepatic steatosis and vascular disease.
    Santoliquido A, Di Campli C, Miele L, Gabrieli ML, Forgione A, Zocco MA, Lupascu A, Di Giorgio A, Flore R, Pola P, Gasbarrini G, Gasbarrini A, Tondi P, Grieco A.
    Eur Rev Med Pharmacol Sci; 2005 Nov; 9(5):269-71. PubMed ID: 16231588
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. [Steatosis and steatohepatitis in diabetic patient].
    Hůlek P, Dresslerová I.
    Vnitr Lek; 2011 Apr; 57(4):364-7. PubMed ID: 21612059
    [Abstract] [Full Text] [Related]

  • 36. Nonalcoholic fatty liver disease.
    Adams LA, Angulo P, Lindor KD.
    CMAJ; 2005 Mar 29; 172(7):899-905. PubMed ID: 15795412
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Current status of liver disease in Korea: nonalcoholic fatty liver disease.
    Park SH.
    Korean J Hepatol; 2009 Dec 29; 15 Suppl 6():S34-9. PubMed ID: 20037278
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Review article: epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease.
    Barshop NJ, Sirlin CB, Schwimmer JB, Lavine JE.
    Aliment Pharmacol Ther; 2008 Jul 29; 28(1):13-24. PubMed ID: 18397387
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.